If earlier α2δ ligands do have efficacy in reducing abdominal pain in IBS, then this efficacy does not extend to all members of this pharmacological class, whether suffering with high levels of pain and/or anxiety or not. This evidence concerns the gene ATXN2L and irritable bowel syndrome.